Increased catecholamine levels in specific brain regions of a rat model of depression: Normalization by chronic antidepressant treatment

Brain Research

Volumn 824, Issue 2, 1999, Pages 243-250

  Zangen, Abraham ^a   Overstreet, David H ^b   Yadid, Gal ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Catecholamines; Dopamine; Norepinephrine; Turnover

Indexed keywords

ANTIDEPRESSANT AGENT; CATECHOLAMINE; DESIPRAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CATECHOLAMINE METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DORSAL RAPHE NUCLEUS; FEMALE; HIPPOCAMPUS; HYPOTHALAMUS; MEDIAN RAPHE NUCLEUS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN MAPPING; CATECHOLAMINES; DEPRESSION; DESIPRAMINE; DISEASE MODELS, ANIMAL; MALE; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SWIMMING; TIME FACTORS;

EID: 0033541514     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01214-7     Document Type: Article

References (37)

1. H.S. Akiskal, Mood disorders: introduction and overview, in: H.I. Kaplan, B.J. Sadock (Eds.), Comprehensive Textbook of Psychiatry, Vol. 6, Williams & Wilkins, Baltimore, 1995, pp. 1067-1068.
2. M. Asberg, L. Bertilsson, B. Martensson, G.P. Scalia, P. Thoren, L. Traskman-Bendz, CSF monoamine metabolites in melancholia, Acta Psychiatr. Scand. 69 (1984) 201-219.
3. N. Bel, F. Artigas, In vivo effects of simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies, J. Pharmacol. Exp. Ther. 287 (1996) 1064-1072.
4. J. Beskow, C.G. Gottfries, B.E. Roos, B. Winblad, Determination of monoamine and monoamine metabolites in the human brain: post mortem studies in a group of suicides and control group, Acta Psychiatr. Scand. 53 (1976) 7-20.
5. F. Borsini, A. Meli, Is the forced swim test a suitable model for revealing antidepressant activity?, Psychopharmacology 94 (1988) 147-160.
6. R.P. Brown, J.H. Kocsis, S. Caroff, J. Amsterdam, A. Winokur, P.E. Stokes, A. Frazer, Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects, Am. J. Psychiatry 142 (1985) 811-816.
7. A.S. Brown, S. Gershon, Dopamine and depression, J. Neural. Transm. 91 (1993) 75-109.
8. M.Y. Chung, D.G. Kim, K.J. Yoo, S.S. Hong, Regional differences in the levels of biogenic amines and their metabolites in rat brain after tricyclic antidepressant treatment, Yonsei Med. J. 34 (1993) 266-277.
9. J.W. Commissiong, Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity, Biochem. Pharmacol. 34 (1985) 1127-1131.
10. M. Elser, J.T. Turbott, R. Schwartz, The peripheral kinetics of norepinephrine in depressive illness, Arch. Gen. Psychiatry 39 (1982) 295-300.
11. M.P. Galloway, M.E. Wolf, R.H. Roth, Regulation of dopamine synthesis in the medial prefrontal cortex is madiated by release modulating autoreceptors: studies in vivo, J. Pharmacol. Exp. Ther. 236 (1986) 689-698.
12. M.P. Galloway, Regulation of dopamine and serotonin synthesis by acute administration of cocaine, Synapse 6 (1990) 63-72.
13. A. Gjerris, L. Werdelin, O.J. Rafealson, C. Alling, N.J. Christensen, CSF dopamine increased in depression: CSF dopamine, noradrenaline and their metabolites in depressed patients and in controls, J. Affect. Disord. 13 (1987) 279-286.
14. B.L. Jacobs, E.C. Azmitia, Structure and function of the brain serotonin system, Physiol. Rev. 72 (1992) 165-229.
15. M.R. Johnson, R.B. Lydiard, W.A. Morton, L.K. Laird, T.E. Steele, C.H. Kellner, J.C. Ballenger, Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients, J. Psychiatr. Res. 27 (1993) 161-172.
16. G.F. Koobs, F.E. Bloom, Cellular and molecular mechanisms of drug dependence, Science 242 (1988) 715-723.
17. D.H. Overstreet, The Flinders sensitive line rats: a genetic animal model of depression, Neurosci. Biobehav. Rev. 17 (1993) 51-68.
18. D.H. Overstreet, O. Pucilowski, A.H. Rezvani, D.S. Janowski, Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression, Psychopharmacology 121 (1995) 27-37.
19. M. Palkovits, M.J. Brownstein, Maps and Guide to Microdissection of the Rat Brain, Elsevier, New York, 1988.
20. C.M.B. Pare, D.P.H. Yeung, K. Price, R.S. Stacey, 5-Hydroxytryptamine, noradrenaline, and dopamine in brainstem, hypothalamus, and caudate nucleus of controls and patients committing suicide by coal-gas poisoning, Lancet ii (1969) 133-135.
21. R.M. Post, C.R. Lake, D.C. Jimerson, W.E. Bunney, J.H. Wood, M.G. Ziegler, F.K. Goodwin, Cerebrospinal fluid norepinephrine in affective illness, Am. J. Psychiatry 135 (1978) 907-912.
22. H.M. van Praag, Biological suicide research: outcome and limitations, Biol. Psychiatry 21 (1986) 1305-1323.
23. O. Pucilowski, D.H. Overstreet, Effect of chronic antidepressants on responses to apomorphine in selectively bred rat strains, Behav. Brain Res. 32 (1993) 471-475.
24. A.J. Rothschild, A.F. Schatzberg, P.J. Langlais, J.E. Lerbinger, M.M. Miller, J.O. Cole, Psychotic and nonpsychotic depression: I. Comparison of plasma catecholamines and cortisol measures, Psychiatry Res. 20 (1987) 143-153.
25. A. Roy, D. Pickar, M. Linnoila, A.R. Doran, P. Ninan, S.M. Paul, Cerebrospinal fluid monoamine metabolite concentrations in melancholia, Psychiatry Res. 15 (1985) 281-292.
26. A. Roy, H. Agren, D. Picker, M. Linnoila, A.R. Doran, N.R. Cutler, S.M. Paul, Reduced cerebrospinal fluid concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratio in depressed patients: relationship to suicidality and dexamethasone nonsupression, Am. J. Psychiatry 143 (1986) 1539-1545.
27. A. Roy, Plasma HVA levels in depressed patients and controls, J. Affect. Disord. 14 (1988) 293-296.
28. J.J. Schildkraut, A. Winokur, C.W. Applegate, Norepinephrine turnover and metabolism in rat brain after long-term administration of imipramine, Science 168 (1970) 867-869.
29. W. Schultz, P. Dayan, P.R. Montague, A neural substrate of prediction and reward, Science 275 (1997) 1593-1596.
30. M.L. Sedlock, D.J. Edwards, Opposite effect of chronic imipramine treatment on brain and urine MHPG levels in the rat, Biol. Psychiatry 20 (1985) 858-865.
31. D.W. Self, E.J. Nestler, Molecular mechanisms of drug reinforcement and addiction, Annu. Rev. Neurosci. 18 (1995) 463-495.
32. L. Serova, E. Sabban, A. Zangen, D.H. Overstreet, G. Yadid, Altered gene expression for catecholamine biosynthetic enzymes and stress response in a rat genetic model of depression, Mol. Brain Res. 63 (1998) 133-138.
33. L. Traskman, M. Asberg, L. Bertilsson, L. Sjostrad, Monoamine metabolites in CSF and suicidal behaviour, Arch. Gen. Psychiatry 38 (1981) 631-636.
34. R.C. Veith, M.A. Raskind, R.F. Barnes, G. Gumbrecht, J.L. Ritchie, J.B. Halter, Tricyclic antidepressants and supine, standing, and exercise plasma norepinephrine levels, Clin. Pharmacol. Ther. 33 (1983) 763-769.
35. R.A. Wise, Neurobiology of addiction, Curr. Opin. Neurobiol. 6 (1996) 243-252.
36. G. Yadid, K. Pacak, I.J. Kopin, D.S. Goldstein, Endogenous serotonin stimulates striatal dopamine release in conscious rats, J. Pharmacol. Exp. Ther. 270 (1994) 1158-1165.
37. A. Zangen, D.H. Overstreet, G. Yadid, High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment, J. Neurochem. 69 (1997) 2477-2483.